Renal complications in oncohematologic patients

Journal of Investigative Medicine

Volumn 57, Issue 8, 2009, Pages 892-901

  Buemi, Michele ^a   Fazio, Maria Rosaria ^a   Bolignano, Davide ^a   Coppolino, Giuseppe ^a   Donato, Valentina ^a   Lacquaniti, Antonio ^a   Mondello, Stefania ^a   Buemi, Antoine ^a   Allegra, Alessandro ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Hematopoietic cell transplant; Hemolytic uremic syndrome; Myeloma; Renal failure; Thrombotic microangiopathy

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALLOPURINOL; AMIFOSTINE; ANGIOGENESIS INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; BLEOMYCIN; BORTEZOMIB; CISPLATIN; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; GLUTATHIONE; IBANDRONIC ACID; IFOSFAMIDE; IMATINIB; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MITOMYCIN C; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; RASBURICASE; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN; ZOLEDRONIC ACID;

BRADYCARDIA; CLINICAL EVALUATION; CONSTIPATION; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; KIDNEY FAILURE; LETHARGY; MYELOMA; NEPHROTOXICITY; NEUROPATHY; NONHUMAN; PATHOPHYSIOLOGY; PROTEINURIA; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR LYSIS SYNDROME;

ANIMALS; ANTINEOPLASTIC AGENTS; HEMATOLOGIC DISEASES; HUMANS; KIDNEY DISEASES; NEOPLASMS;

EID: 74249120142     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181c5e762     Document Type: Review

References (133)

1. Kapoor M, Chan GZ. Malignancy and renal disease. Crit Care Clin. 2001;17:571-598.
2. da Silva J, Mesler D. Acute renal failure as a result of malignancy. In: Molitoris B, Finn W, eds. Acute Renal Failure: A Companion to Brenner and Rector's The Kidney. Indianapolis, IN: Harcourt; 2001: 312-321.
3. Blade J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889-1893.
4. Coggins CH. Renal failure in lymphoma. Kidney Int. 1980;17: 847-855.
5. Richmond J, Sherman RS, Diamond HD, et al. Renal lesions associated with malignant lymphomas. Am J Med. 1962;32:184-207.
6. Wagle DG, Moore RH, Murphy GP. Secondary carcinomas of the kidney. J Urol. 1975;114:30-32.
7. Manning EC, Belenko MI, Frauenhoffer EE, et al. Acute renal failure secondary to solid tumor renal metastases: case report and review of the literature. Am J Kidney Dis. 1996;27:284-291.
8. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48:337-341.
9. Batuman V, Verroust PJ, Navar GL, et al. Myeloma light chain are ligands for cubilin (gp280). Am J Physiol. 1998;275:F246-254.
10. Santostefano M, Zanchelli F, Zaccaria A, et al. The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol. 2005; 18:659-675.
11. Ying WZ, Sanders PW. Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol. 2001;158:1859-1866.
12. Ronco P, Plaisier E, Mougenot B, et al. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. Clin J Am Soc Nephrol. 2006;1: 1342-1350.
13. Ma CX, Lacy MQ, Rompala JF, et al. Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood. 2004;104:40-42.
14. Keeling J, Herrera GA. The mesangium as target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. Contrib Nephrol. 2007;153: 116-134.
15. Contè LG, Figueroa MG, Lois VV, et al. Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system. Rev Med Chil. 2008;136:7-12.
16. Mayo MM, Johns GS. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias. Contrib Nephrol. 2007;153:44-65.
17. Zucchelli P, Pasquali S, Cagnoli L, et al. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988;33:1175-1180.
18. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143:777-784.
19. Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiplemyeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18: 886-895.
20. Hutchison CA, Cook M, Basu S, et al. Combined chemotherapy and high cut-off hemodialysis improve outcomes in multiple myeloma patients with severe renal failure [abstract]. Blood. 2007;110:3610.
21. Tosi P, Zamagni E, Cellini C, et al. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004;73:98-103.
22. Pineda-Roman M, Tricot G. High dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol. 2007;153: 182-194.
23. Niesvizky R, Naib T, Cristos PJ, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naBve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol. 2007;138: 640-643.
24. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naBve symptomatic multiple myeloma. Blood. 2008;111:1101-1109.
25. San-Miguel JF, Richardson PG, Sonneveld P, et al. Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 2008;22:842-849.
26. Ludwig H, Drach J, Graf H, et al. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007;92:1411-1414.
27. 2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant. 2005;35:985-990.
28. Gertz MA, Lacy MQ, Dispenzieri A, et al. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant. 2007;39:605-611.
29. Jeha S. Tumor lysis syndrome. Semin Hematol. 2001;38(suppl 10):4-8.
30. Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-554.
31. Conger JD. Acute uric acid nephropathy. Med Clin North Am. 1990; 74:859-871.
32. Johnson RJ, Kivlighn SD, Kim YG, et al. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis. 1999;33:225-234.
33. Jerome KR, Corey L. The danger within. N Engl J Med. 2004;350: 411-412.
34. Boles JM, Dutel JL, Briere J, et al. Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer. 1984;53:2425-2429.
35. Zager RA. Hyperphosphatemia: a factor that provokes severe experimental acute renal failure. J Lab Clin Med. 1982;100:230-239.
36. Altman A. Acute tumor lysis syndrome. Semin Oncol. 2001; 28(suppl 5):3-8.
37. Sezer O, Vesole DH, Singhal S, et al. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma. 2006;7: 233-235.
38. Frei E 3rd, Bentzel CJ, Rieselbach R, et al. Renal complications of neoplastic disease. J Chronic Dis. 1963;16:757-776.
39. Kjellstrand CM, Cambell DC 2nd, von Hartitzsch B, et al. Hyperuricemic acute renal failure. Arch Intern Med. 1974;133:349-359.
40. Ronco C, Bellomo R, Inguaggiato P, et al. Rasburicase therapy in acute hyperuricemic renal dysfunction. Contrib Nephrol. 2004;144: 158-165.
41. Leach M, Parsons RM, Reilly JT, et al. Efficacy of urate oxidase (uricozyme) in tumour lysis induced urate nephropathy. Clin Lab Haematol. 1998;20:169-172.
42. Wolf G, Hegewisch-Becker S, Hossfeld DK, et al. Hyperuricemia and renal insufficiency associated with malignant disease: urate oxidase as an efficient therapy? Am J Kidney Dis. 1999;34:E20.
43. van den Berg H, Reintsema AM. Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol. 2004;15:175-176.
44. Maesaka JK, Mittal SK, Fishbane S. Paraneoplastic syndromes of the kidney. Semin Oncol. 1997;24:373-381.
45. Bacchetta J, Juillard L, Cochat P, et al. Paraneoplastic glomerular disease and malignancies. Crit Rev Oncol Hematol. 2009;70:39-58.
46. Eagen JW. Glomerulopathies of neoplasia. Kidney Int. 1977;11:297-303.
47. Pankhurst T, Savage CO, Gordon C, et al. Malignancy is increased in ANCA-associated vasculitis. Rheumatology (Oxford). 2004;43: 1532-1535.
48. Edgar JD, Rooney DP, McNamee P, et al. An association between ANCA positive renal disease and malignancy. Clin Nephrol. 1993; 40:22-25.
49. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002;100:82-85. (Pubitemid 34602069)
50. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002; 347:589-600.
51. George JN, Selby GB. Thrombotic microangiopathy after allogenic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes. Bone Marrow Transplant. 2004;33: 1073-1074.
52. Halevy D, Radhakrishnan J, Markowitz G, et al. Thrombotic microangiopathies. Crit Care Clin. 2002;18:309-320, vi.
53. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60:831-846. (Pubitemid 34205784)
54. Antman KH, Skarin AT, Mayer RJ, et al. Microangiopathic hemolytic anemia and cancer: a Review. Medicine (Baltimore). 1979;58:377-384.
55. Lohrmann HP, Adam W, Heymer B, et al. Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med. 1973;79:368-375.
56. Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol. 1987;24:161-177.
57. Valavaara R, Nordman E. Renal complications of mitomycin C therapy with special reference to the total dose. Cancer. 1985;55:47-50.
58. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpuraYhemolytic uremic syndrome. Curr Opin Hematol. 2001;8:286-293.
59. Fung MC, Storniolo AM, Nguyen B, et al. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999;85:2023-2032.
60. Flombaum CD, Mouradian JA, Casper ES, et al. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis. 1999;33:555-562.
61. Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9(suppl 4): 28-37.
62. Shreedhara M, Fenves AZ, Stone MJ. Reversibility of pamidronate- associated glomerulosclerosis. Proc (Bayl Univ Med Cent). 2007;20:249-253.
63. Desikan R, Veksler Y, Raza S. Nephrotic proteinuria associated with high dose pamidronate in multiple myeloma. Br J Haematol. 2002; 119:496-499.
64. Braun JP, Rico AG, Benard P. Urinary gamma-glutamyl transferase in renal toxicology of the rat. Basis of its use and significance in acute mercurial nephritis. Toxicology. 1978;11:73-82.
65. Laurinacicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int. 1999;56:2203-2213.
66. Barri YM, Munshi NC, Sukumalchantra S, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int. 2004;65:634-641.
67. Bounameaux HM, Schiifferli J, Montani JP. Renal failure associated with intravenous disphosphonates. Lancet. 1983;I:471.
68. Yates AJP, Gray RES, Urwin GH. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet. 1985;I:1474-1477.
69. Dumon JC, Magritte A, Body JJ. Efficacy and safety of the bisphosphanate tiludronate for the treatment of tumor associated hypocalcaemia. Bone Miner. 1991;15:257-266.
70. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164-1172.
71. Kunin M, Kopolovic J, Avigdor A, et al. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant. 2004;19:723-726.
72. D'Agati V, Suh JI, Carbone L, et al. Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int. 1989;35:1358-1370.
73. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003; 64:281-289.
74. Banerjee D, Asif A, Striker L, et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis. 2003;41:E18.
75. Smetana S, Michlin A, Rosenman E, et al. Pamidronate-induced nephrotoxic tubular necrosisVa case report. Clin Nephrol. 2004;61:63-67.
76. Rosen LS, Gordon D, Kaminski M. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.
77. Rosen LS, Gordon D, Kaminski M. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744.
78. Saad F, Gleason DM, Murray R. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
79. Rosen LS, Gordon D, Tchekmedyian S. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trialVthe Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150-3157.
80. Rosen LS, Gordon D, Tchekmedyian NS. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-2621.
81. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003;349(17):1676-1679.
82. Novartis Pharmaceuticals Corporation. Prescribing information. Aredia (pamidronate). Available at: http://www.pharma.us.novartis.com/product/pi.jsp. Accessed May 25, 2006.
83. Novartis Pharmaceuticals Corporation. Prescribing information. Zometa (zoledronic acid). Available at: http://www.pharma.us.novartis.com/product/pi. jsp. Accessed May 25, 2006.
84. Ali SM, Esteva FJ, Hortobagyi G. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol. 2001;19:3434-3437.
85. Guarneri V, Donati S, Nicolini M. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist. 2005;10:842-848.
86. Guarneri V, Donati S, Nicolini M, et al. Renal safety of zoledronic acid in patients with bone metastases from breast cancer or other tumors treated with intravenous bisphosphonates for up to ten years. Ann Oncol. 2004;15:811.
87. Rosen LS, Gordon D, Tchekmedyan S. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial. J Clin Oncol. 2003;21:3150-3157.
88. Jackson GM. Renal safety of ibandronate. Oncologist. 2005; 10(suppl 1):14-18.
89. Hillner BE, Ingle JN, Chlebowski RT. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2004;22:1351.
90. Safirstein RL. Renal diseases induced by antineoplastic agents. In: Schrier RW, ed. Diseases of the Kidney and Urinary Tract. Philadelphia, PA: Lippincott; 2001:1175-1188.
91. Darmon M, Ciroldi M, Thiery G, et al. Clinical review: specific aspects of acute renal failure in cancer patients. Crit Care. 2007;10(2):211.
92. Langerak AD, Dreisbach LP. Chemotherapy Regimens and Cancer Care. Georgetown, TX: Landes Bioscience; 2001.
93. Curran WJ. New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology. 2002;63(suppl 2):29-38.
94. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, et al. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 1977;39:1362-1371.
95. Ali BH, Al-Moundhri M, Tageldin M, et al. Ontogenic aspects of cisplatin-induced nephrotoxicity in rats. Food Chem Toxicol. 2008;46:3355-3359.
96. Barabas K, Milner R, Lurie D, et al. Cisplatin: a reviewof toxicities and therapeutic applications. Vet Comp Oncol. 2008;6:1-18.
97. Hanigan MH, Gallagher BC, Taylor PT Jr, et al. Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res. 1994;54: 5925-5929.
98. Hanigan MH, Gallagher BC, Townsend DM, et al. Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis. 1999;520:553-559.
99. Hanigan MH, Lykissa ED, Townsend DM, et al. Gamma-glutamyl transpeptidaseYdeficient mice are resistant to the nephrotoxicity of cisplatin. Am J Pathol. 2001;159:1889-1894.
100. Wainford RD, Weaver RJ, Stewart KN, et al. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology. 2008;249: 184-193.
101. Francescato HD, Costa RS, da Silva CG, et al. Treatment with a p38 MAPK inhibitor attenuates cisplatin nephrotoxicity starting after the beginning of renal damage. Life Sci. 2009;84:590-597.
102. Kang KP, Kim DH, Jung YJ, et al. Alpha-lipoic acid attenuates cisplatin-induced acute kidney injury in mice by suppressing renal inflammation. Nephrol Dial Transplant. 2009;24:3012-3020.
103. Launay-Vacher V, Rey J-B, Isnard-Bagnis C, et al. Prevention of cisplatin nephrotoxixity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008;61:903-909.
104. Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res. 2009; 33:344-347.
105. François H, Coppo P, Hayman JP, et al. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss. Am J Kidney Dis. 2008;51:298-301.
106. Gibbons J, Egorin MJ, Ramanathan RK, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008;4:570-576.
107. Izzedine H, Rixe O, Billemont B, et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007;50:203-218. (Pubitemid 47095077)
108. Halimi JM, Azizi M, Bobrie G, et al. Vascular and renal effects of anti-angiogenic therapy. Nephrol Ther. 2008;4:602-615.
109. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med. 2009;122:322-328.
110. Stokes MB, Erazo MC, D'Agati VD. Glomerular disease related to anti-VEGF therapy. Kidney Int. 2008;74:1487-1491.
111. Veremina JA, Kowalewska JJ, Hochster H, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;11: 1129-1136.
112. Zager RA, O'Quigley J, Zager BK, et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis. 1988;13:210-216.
113. Hahn T, Rondeau C, Shaukat A, et al. Acute renal failure requiring dialysis after allogenic blood and marrow transplantation identifies very poor prognosis patients. Bone Marrow Transplant. 2003;32: 405-410.
114. Parikh CR, McSweeney PA, Korular D, et al. Renal dysfunction in allogenic hematopoietic cell transplantation. Kidney Int. 2002;62: 566-573.
115. Noel C, Hazzan M, Noel-Walter MP, et al. Renal failure and bone marrow transplantation. Nephrol Dial Transplant. 1998;13: 2464-2466.
116. Zager RA. Acute renal failure in the setting of bone marrow transplantation. Kidney Int. 1994;46:1443-1458.
117. Alessandrino EP, Bernasconi P, Caldera D, et al. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:607-612.
118. Smith DM, Weisenburger DD, Bierman P, et al. Acute renal failure associated with autologous bone marrow transplantation. Bone Marrow Transplant. 1987;2:195-201.
119. Cohen EP. Renal failure after bone-marrow transplantation. Lancet. 2001;357:6-7.
120. Cohen EP, Hussain S, Moulder JE. Successful treatment of radiation nephropathy with angiotensin II blockade. Int J Radiat Oncol Biol Phys. 2003;55:190-193.
121. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:328-336.
122. Cohen EP, Robbins ME. Radiation nephropathy. Semin Nephrol. 2003;23:486-499.
123. Cohen EP. Radiation nephropathy after bone marrow transplantation. Kidney Int. 2000;58:903-918.
124. Liu H, Ding JH, Liu BC, et al. Early renal injury after nonmyeloablative allogeneic peripheral blood stem cell transplantation in patients with chronic myelocytic leukemia. Am J Nephrol. 2007; 27(4):336-341.
125. Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;12:4425-4431.
126. Eknoyan G. Meeting the challenges of the new K/DOQI guidelines. Am J Kidney Dis. 2003;41(suppl):3-10.
127. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004; 351:585-592.
128. Cohen EP, Piering WF, Kabler-Babbitt C, et al. Endstage renal disease (ESRD) after bone marrow transplantation: poor survival compared to other causes of ESRD. Nephron. 1998;79:408-412.
129. Chang JW, Tsai HL, Wang HH, et al. Outcome and risk factors for mortality in children with acute renal failure. Clin Nephrol. 2008;70: 485-489.
130. Leung AY, Mak R, Lie AK, et al. Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Bone Marrow Transplant. 2002;29:509-513.
131. Comar M, D'Agaro P, Andolina M, et al. Hemorrhagic cystitis in children undergoing bone marrow transplantation: a putative role for simian virus. Transplantation. 2004;78:544-548.
132. Mori K, Yoshihara T, Nishimura Y, et al. ARF due to adenovirus-associated obstructive uropathy and necrotizing tubulointerstitial nephritis in a bone marrow transplant recipient. Bone Marrow Transplant. 2003;31:1173-1176.
133. Benoit DD, Depuydt PO, Vandewoude KH, et al. Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies. Nephrol Dial Transplant. 2005;20: 552-558.